To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN

NCT00302549 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: FK506

Sponsor

Nanjing University School of Medicine

Collaborators

[object Object]